Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | EVP R&D, Chief Medical Officer | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 65,389 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 5,000 · Balance 74,389 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. Row 2 · 2026-09-01 · Sale · Disposed 9,000 · Balance 65,389 F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.59 · Expires 2032-02-18 | Direct | 61,276 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Disposed 5,000 · Balance 61,276 F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025. F4: These options are fully vested in accordance with their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.8269 to $47.3197. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F4: These options are fully vested in accordance with their terms.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBIREO PHARMA, INC.
Report date March 02, 2023 · Filed March 02, 2023
Section 16 reporting ended · disclosed 2023-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-02 · Disposition to issuer · Disposed 10,495 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share"). F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F5: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share").
F2: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time").
F3: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027;
F4: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect.
F5: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 12,411 | $26.82 | $332,863.02 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 12,044 | $24.59 | $296,161.96 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 12,090 | $19.34 | $233,820.60 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:53 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 12,452 | $20.03 | $249,413.56 |
DisclosureSEC source: 0001127602-24-028885 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| December 05, 2024 Filed Dec 5, 2024 23:01 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 9,221 | $31.50 | $290,461.50 |
DisclosureSEC source: 0001127602-24-028740 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,730 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| December 04, 2024 Filed Dec 4, 2024 21:52 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 14,349 | $30.77 | $441,550.30 |
DisclosureSEC source: 0001127602-24-028647 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,951 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.50 to $31.00. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 21:48 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 43,058 | $0.00 Strike: $20.03 | $0.00 |
DisclosureSEC source: 0001127602-24-027044 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,174 Underlying: Ordinary Shares · 43,058 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F4 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 21:48 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 58,996 | $30.08 | $1,774,576.08 |
DisclosureSEC source: 0001127602-24-027044 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,300 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.20. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 21:48 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 43,058 | $20.03 | $862,451.74 |
DisclosureSEC source: 0001127602-24-027044 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. Read SEC document |
| November 06, 2024 Filed Nov 7, 2024 00:47 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 10,471 | $29.53 | $309,168.84 |
DisclosureSEC source: 0001127602-24-026629 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,238 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.50 to $29.61. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:03 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 27,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-007138 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,464 Underlying: Ordinary Shares · 27,464 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:03 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 111,186 | $0.00 Strike: $30.04 | $0.00 |
DisclosureSEC source: 0001127602-24-007138 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,186 Underlying: Ordinary Shares · 111,186 shares Expires 2034-02-26 F3 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/26/2025. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:03 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 7,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-007138 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,068 Underlying: Ordinary Shares · 7,689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:03 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,414 | $29.57 | $100,951.98 |
DisclosureSEC source: 0001127602-24-007138 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,709 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:03 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 7,689 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-007138 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:07 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 12,278 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006562 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,279 Underlying: Ordinary Shares · 12,278 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:07 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 5,452 | $28.91 | $157,617.32 |
DisclosureSEC source: 0001127602-24-006562 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,434 Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:07 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 12,278 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006562 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 22:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 10,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · derivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 22:32 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 4,572 | $30.39 | $138,943.08 |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,608 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 22:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 10,297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · nonDerivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,793 Underlying: Ordinary Shares · 8,897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:32 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,951 | $32.18 | $127,143.18 |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,883 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:32 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 15,280 | $26.77 | $409,045.60 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,937 Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | GrantOrdinary Shares | 46,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,217 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 603 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 13 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,757 Underlying: Ordinary Shares · 603 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F12 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. F12 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 2,412 | $26.82 Strike: $26.82 | $64,689.84 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 12 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,027 Underlying: Ordinary Shares · 2,412 shares Expires 2033-02-23 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F11 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 11 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,690 Underlying: Ordinary Shares · 523 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F10 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F10 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 2,790 | $24.59 Strike: $24.59 | $68,606.10 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 10 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,344 Underlying: Ordinary Shares · 2,790 shares Expires 2032-02-18 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F9 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 9 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,557 Underlying: Ordinary Shares · 481 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 3,929 | $19.34 Strike: $19.34 | $75,986.86 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 8 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,413 Underlying: Ordinary Shares · 3,929 shares Expires 2031-02-22 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F7 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 201 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 7 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,297 Underlying: Ordinary Shares · 201 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F6 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. F6 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 3,376 | $20.03 Strike: $20.03 | $67,621.28 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,232 Underlying: Ordinary Shares · 3,376 shares Expires 2030-02-20 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 2,133 | $31.93 Strike: $31.93 | $68,106.69 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,833 Underlying: Ordinary Shares · 2,133 shares Expires 2029-02-21 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 1,089 | $65.94 Strike: $65.94 | $71,808.66 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,589 Underlying: Ordinary Shares · 1,089 shares Expires 2028-02-16 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC | Alkermes plc. ALKS · Entity 2392 | OtherEmployee Stock Option (Right to Buy) · Derivative | 1,599 | $58.40 Strike: $58.40 | $93,381.60 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,599 Underlying: Ordinary Shares · 1,599 shares Expires 2027-06-07 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| March 02, 2023 Filed Mar 2, 2023 16:39 UTC | ALBIREO PHARMA, INC. ALBO · Entity 116015 | Disposition to issuerRestricted Stock Units · Derivative | 10,495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-014724 · doc4.xml · derivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,495 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer, $0.01 par value per share (each, a "Share"). F2 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3 · price: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4 · price: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F2 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 8, 2023, (the "Merger Agreement"), among Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("Parent"), Anemone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"), solely for purposes of Sections 9.5, 9.6, 9.8 and 9.11 thereof, Ipsen Pharma SAS, a French societe par actions simplifiee ("Guarantor"), and the Issuer, pursuant to which Purchaser completed a tender offer for Share and thereafter merged with and into the Issuer (the "Merger"), effective as of March 2, 2023 (the "Effective Time"). F3 · derivative.exercise_date: (Continued from Footnote 2) At the Effective Time, (a) each outstanding restricted stock unit (each, a "Company RSU") that was granted prior to the date of the Merger Agreement, and each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as an "Accelerated 2023 RSU," was canceled and converted into the right to receive (1) cash in an amount, without interest, equal to the product of (x) the total number of Shares subject to such Company RSU immediately prior to the Effective Time multiplied by (y) $42.00 and (2) one non-tradeable contractual contingent value right ("CVR") for each Share subject to such Company RSU immediately prior to the Effective Time, which CVR represents the right to receive a contingent payment of $10.00, net to the holder in cash, without interest, upon the achievement of the milestone set forth in a certain Contingent Value Rights Agreement on or prior to December 31, 2027; F4 · derivative.exercise_date: (Continued from Footnote 3) and (b) each Company RSU that was granted on or after the date of the Merger Agreement and that is designated in the confidential disclosure schedules as a "Cancelled 2023 RSU" was canceled and had no further force or effect. F5 · derivative.expiration_date: Not applicable. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:23 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 30,154 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-007180 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,154 Underlying: Ordinary Shares · 30,154 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:23 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 120,615 | $0.00 Strike: $27.36 | $0.00 |
DisclosureSEC source: 0001127602-23-007180 · form4.xml · derivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,615 Underlying: Ordinary Shares · 120,615 shares Expires 2033-02-23 F3 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:23 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 12,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-007180 · form4.xml · derivative · entry 3 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,076 Underlying: Ordinary Shares · 12,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:23 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 5,345 | $27.77 | $148,430.65 |
DisclosureSEC source: 0001127602-23-007180 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,559 Read SEC document |
| February 22, 2023 Filed Feb 25, 2023 01:23 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 12,038 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-007180 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · derivative · entry 11 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: This award is fully vested in accordance with its terms. F5 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,053 | $27.77 | $84,781.81 |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · nonDerivative · entry 8 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,866 Read SEC document |
| February 21, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · nonDerivative · entry 7 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 10,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · derivative · entry 10 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,096 Underlying: Ordinary Shares · 10,095 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021. Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 6,526 | $28.07 | $183,184.82 |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · nonDerivative · entry 6 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,044 Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | GrantOrdinary Shares | 22,195 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · nonDerivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,570 F2 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 20, 2020 with a three-year performance period that ended on December 31, 2022 (the "2020 PRSUs"). The vesting of this portion of the 2020 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2020 PRSUs. Read SEC document |
| February 20, 2023 Filed Feb 22, 2023 21:56 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 3,780 | $28.07 | $106,104.60 |
DisclosureSEC source: 0001127602-23-006511 · form4.xml · nonDerivative · entry 4 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,375 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.